FDA-approved Product 1
Complications of Kidney Disease
ApprovedCommercial
Key Facts
About Akebia Therapeutics
Founded in 2007, Akebia Therapeutics has established itself as a leader in the renal community, dedicated to bettering the lives of those impacted by kidney disease. The company has built a fully integrated organization with a nephrology-focused commercial team and a robust R&D engine centered on oral HIF-PH inhibitors. With two FDA-approved products and a late-stage candidate, vadadustat, in development for anemia due to chronic kidney disease, Akebia aims to address significant unmet needs and set new standards of care.
View full company profileTherapeutic Areas
Other Complications of Kidney Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| FDA-approved Product 2 | Akebia Therapeutics | Approved |